title: 1:1 atrial-flutter. Prevalence and clinical characteristics.
abstract: Little is known about the epidemiology of 1:1 atrial flutter (AFL). Our objectives were to determine its prevalence and predisposing conditions.
  
  
  METHODS
  1037 patients aged 16 to 93 years (mean 64±12) were consecutively referred for AFL ablation. 791 had heart disease (HD). Patients admitted with 1/1 AFL were collected. Patients were followed 3±3 years.
  
  
  RESULTS
  1:1 AFL-related tachycardiomyopathy was found in 85 patients, 59 men (69%) with a mean age of 59±12 years. The prevalence was 8%. They were compared to 952 patients, 741 men (78%, 0.04), with a mean age of 65±12 years (0.002) without 1:1 AFL. Factors favoring 1:1 AFL was the absence of HD (35 vs 23%, 0.006), the history of AF (42 vs 30.5%)(0.025) and the use of class I antiarrhythmic drugs (34 vs 13%)(p<0.0001), while use of amiodarone or beta blockers was less frequent in patients with 1:1 AFL (5, 3.5%) than in patients without 1:1 AFL (25, 15%) (p<0.0001, 0.03). The failure of ablation (9.4 vs 11%), ablation-related complications (2.3 vs 1.4%), risk of subsequent atrial fibrillation (AF) (20 vs 24%), risk of AFL recurrences (19 vs 13%) and risk of cardiac death (5 vs 6%) were similar in patients with and without 1:1 AFL.
  
  
  CONCLUSIONS
  The prevalence of 1:1 AFL in patients admitted for AFL ablation was 8%. These patients were younger, had less frequent HD, had more frequent history of AF and received more frequently class I antiarrhythmic drugs than patients without 1:1 AFL. Their prognosis was similar to patients without 1:1 AFL.
authors.affiliation: Department of Cardiology, Nancy University Hospital, Rue du Morvan 54511 Vandoeuvre-les-Nancy, France. Electronic address: b.brembilla-perrot@chu-nancy.fr.
authors.forename: Béatrice
authors.initials: B
authors.lastname: Brembilla-Perrot
authors.forename: Franck
authors.initials: F
authors.lastname: Laporte
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Sellal
authors.forename: Jérôme
authors.initials: J
authors.lastname: Schwartz
authors.forename: Arnaud
authors.initials: A
authors.lastname: Olivier
authors.forename: Pierre Yves
authors.initials: PY
authors.lastname: Zinzius
authors.forename: Vladimir
authors.initials: V
authors.lastname: Manenti
authors.forename: Daniel
authors.initials: D
authors.lastname: Beurrier
authors.forename: Marius
authors.initials: M
authors.lastname: Andronache
authors.forename: Pierre
authors.initials: P
authors.lastname: Louis
authors.forename: Olivier
authors.initials: O
authors.lastname: Selton
authors.forename: Arnaud Terrier
authors.initials: AT
authors.lastname: de la Chaise
authors.forename: Christian
authors.initials: C
authors.lastname: De Chillou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001282:Atrial Flutter / Q000175:diagnosis* / Q000453:epidemiology* / Q000601:surgery; D017115:Catheter Ablation / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance / Q000379:methods; D015995:Prevalence; D012189:Retrospective Studies; D055815:Young Adult
keywords: 1:1 atrial flutter; Ablation; Anti-arrhythmic drugs; Atrial flutter; Proarrhythmic effect